100 related articles for article (PubMed ID: 7482116)
1. [Influence of hematopoietic growth factors on transfusion support following autologous bone marrow transplantation].
Galende J; Rodríguez MJ; Nieto MJ; Caballero MD; Vázquez L; Sánchez San Fructuoso C; Corral M
Sangre (Barc); 1995 Aug; 40(4):281-7. PubMed ID: 7482116
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.
Spitzer G; Adkins D; Mathews M; Velasquez W; Bowers C; Dunphy F; Kronmueller N; Niemeyer R; McIntyre W; Petruska P
Bone Marrow Transplant; 1997 Dec; 20(11):921-30. PubMed ID: 9422470
[TBL] [Abstract][Full Text] [Related]
4. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF.
Jansen J; Thompson EM; Hanks S; Greenspan AR; Thompson JM; Dugan MJ; Akard LP
Bone Marrow Transplant; 1999 Jun; 23(12):1251-6. PubMed ID: 10414911
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
7. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor after autologous marrow transplantation for Hodgkin's disease.
Klingemann HG; Wilkie-Boyd K; Rubin A; Onetto N; Nantel SH; Barnett MJ; Reece DE; Shepherd JD; Phillips GL
Biotechnol Ther; 1994; 5(1-2):1-13. PubMed ID: 7703829
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
[TBL] [Abstract][Full Text] [Related]
11. High dose therapy and autologous bone marrow versus blood cell rescue. South Island Bone Marrow Transplant Unit.
Hill GR; Inder A; Patton WN; Hart DN
N Z Med J; 1996 Feb; 109(1016):45-8. PubMed ID: 8598936
[TBL] [Abstract][Full Text] [Related]
12. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO
Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099
[TBL] [Abstract][Full Text] [Related]
13. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
14. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
[TBL] [Abstract][Full Text] [Related]
15. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.
Bolwell BJ; Goormastic M; Yanssens T; Dannley R; Baucco P; Fishleder A
Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072
[TBL] [Abstract][Full Text] [Related]
16. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R
Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
Elkordy M; Crump M; Vredenburgh JJ; Petros WP; Hussein A; Rubin P; Ross M; Gilbert C; Modlin C; Meisenberg B; Coniglio D; Rabinowitz J; Laughlin M; Kurtzberg J; Peters WP
Bone Marrow Transplant; 1997 Feb; 19(4):315-22. PubMed ID: 9051240
[TBL] [Abstract][Full Text] [Related]
18. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
19. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]